Human models as tools in the development of psychotropic drugs by Gilles, Christian et al.
hase 1 studies constitute a pivotal step in drug
development.Their goal is to gather enough information
to warrant the scientific value of phase 2 studies.The infor-
mation to be collected includes the pharmacological
actions of the drug,its side effects with increasing doses,its
pharmacokinetics (PK) and metabolism,its mechanisms
of action,and,if possible,early evidence of effectiveness.
1
The classic method of conducting phase 1 studies is much
more limited (Table I).First-time-in-man,single-dose,and
repeated-dose studies are carried out in healthy volunteers
(HV),according to a parallel,double-blind (DB),placebo-
controlled design.They are focused on PK,safety,and tol-
erability, seeking the maximal tolerated dose (MTD),
which will be the basis for the choice of doses in subse-
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P
Despite the growing means devoted to research and development (R & D) and refinements in the preclinical stages,
the efficiency of central nervous system (CNS) drug development is disappointing. Many drugs reach patient studies with
an erroneous therapeutic indication and/or in incorrect doses. Apart from the first clinical studies, which are conducted
in healthy volunteers and focus only on safety, tolerability, and pharmacokinetics, drug development mostly relies on
patient studies. Psychiatric disorders are characterized by heterogeneity and a high rate of comorbidity. It is becoming
increasingly difficult to recruit patients for clinical trials and there are many confounding factors in this population, for
example, those related to treatments. In order to keep patient exposure and financial expenditure to a minimum, it is
important to avoid ill-designed and inconclusive studies. This risk could be minimized by gathering pharmacodynamic
data earlier in development and considering that the goal of a phase 1 plan is to reach patient studies with clear ideas
about the compound’s pharmacodynamic profile, its efficacy in the putative indication (proof of concept), and phar-
macokinetic/pharmacodynamic relationships, in addition to safety, tolerability, and pharmacokinetics. Human models in
healthy volunteers may be useful tools for this purpose, but their use necessitates a global adaptation of the phase 1
scheme, favoring pharmacodynamic assessments without neglecting safety. We are engaged in an R & D program aimed
to adapt existing models and develop new paradigms suitable for early proof of concept substantiation.
Dialogues Clin Neurosci. 2002;4:377-387.quent patient studies.Using this scheme,many drugs have
been developed in the wrong indication
2 or using inap-
propriate doses,
3 which led to failures or irrelevant stud-
ies, which then had to be replicated leading to delays,
increased costs,and overexposure of patients to drugs.
It seems clear that gathering data on pharmacodynamics
(PD) and PK/PD relationships earlier would minimize
these risks,bearing in mind that,in any case,further steps
will face other major issues such as patient heterogene-
ity and placebo response.
Our usual way of conducting phase 1 studies takes these
needs into account (Table I).As early as in the first-in-
man study,in addition to PK and safety/tolerability eval-
uation,we collect basic,central nervous system (CNS)
PD data,as well as peripheral PD data (eg,evidence of
blood–brain barrier crossing, QTc or cardiac rhythm
changes, minimal active dose, and dose effect), and
attempt to sketch PK/PD relationships.This information
is expanded in repeated-dose studies,which can be fol-
lowed by PD studies in HV, conducted according to a
crossover,DB,placebo-controlled design and using the
most appropriate tools,such as wake or sleep electroen-
cephalography (EEG),cognition or functional imaging
according to the molecule and its putative indication (see,
for example,references 4 to 10).This allows patient stud-
ies to be undertaken with a better knowledge of the drug
profile and the most appropriate doses.
In the last years, the necessity for a proof of concept
(POC) approach has emerged.Simply stated,POC means
that at some stage of the development,before launching
large patient studies,it should be demonstrated that the
drug does what it is supposed to do.Classically,POC stud-
ies are patient studies.Psychiatric disorders are highly het-
erogeneous syndromes,with a high rate of comorbidity
(eg,dementia or schizophrenia coexist with affective or
anxiety disorders,affective disorders with anxiety disor-
ders,different anxiety disorders together,etc).Therefore,
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Selected abbreviations and acronyms
AD Alzheimer’s disease
BZD benzodiazepine
DB double-blind (study)
fMRI functional magnetic resonance imaging
HV healthy volunteer
MTD maximal tolerated dose
PD pharmacodynamics
PK pharmacokinetics 
POC proof of concept
Table I. Three ways of conducting phase 1 studies. MTD, maximal tolerated dose; PK, pharmacokinetics; PD, pharmacodynamics; BBB, blood–brain
barrier. *Basic PD includes BBB crossing, minimal active dose, dose effect, and non–central nervous system (CNS) PD. **Basic PD without BBB
crossing. ***Refined PD (model): proof of concept, minimal active dose, dose effect, and non-CNS PD.
Classic Current (usual) Enhanced
Single-dose study
Population Young, healthy volunteers Young, healthy volunteers Young, healthy volunteers
Design Parallel, double-blind, vs placebo Parallel, double-blind, vs placebo Parallel, double-blind, vs placebo
Objectives • Safety/tolerability (MTD) • Safety/tolerability (MTD) • Safety/tolerability (MTD)
• PK • PK • PK
• Basic PD* • Basic PD*
• PK/PD relationships • PK/PD relationships
Repeated-dose study
Population Healthy volunteers Healthy volunteers Healthy volunteers
Design Parallel, double-blind, vs placebo Parallel, double-blind, vs placebo Crossover, double-blind, vs placebo
Objectives • Safety/tolerability (MTD) • Safety/tolerability (MTD) • Safety/tolerability (MTD)
• PK • PK • PK
• Basic PD** • Refined PD (model)***
• PK/PD relationships • PK/PD relationships
Next step
Population Patients Healthy volunteers Patients
Design Parallel, double-blind, vs placebo Crossover, double-blind, vs placebo Parallel, double-blind, vs placebo
Objectives • Safety • Refined PD • Safety
• Efficacy • PK/PD relationships  • Efficacyessentially two strategies are possible to improve patient
recruitment.The first is to recruit small, homogeneous
groups of highly characterized patients (no comorbidity,
homogeneous symptomatic profile,imaging or biological
characteristics,such as genotype,if applicable,etc),which
is an ambitious and lengthy operation.The second is to
increase the sample size,with the hope that number will
compensate for heterogeneity.This also makes the trial
longer and more expensive,and there is no guarantee that
the compensation will be obtained.In addition,concern
about withdrawing an ongoing treatment on the part of
ethics committees,physicians,nurses,families,and patients
further hampers recruitment.
Studies in HVs have advantages that compensate for
these difficulties. HVs are easier to recruit.They make
more homogeneous—or less heterogeneous—popula-
tions than patients and,since more subjects are available,
homogeneity can be improved through specific selection
criteria.By definition,these subjects are healthy,have a
lower risk of complications,and tolerate procedures bet-
ter.In addition,they have no expectations about the treat-
ment,which can minimize placebo/nocebo effects.By def-
inition,they are also volunteers and get paid,and are thus
more compliant.
Conducting POC studies in HVs implies the recourse to
models or symptom provocation.These challenges can be
understood as the provocation not of a complete clinical
picture,but of some core signs and symptoms.The goal
can be to produce and study functional markers because
they are often more sensitive—and hopefully more reli-
able—than clinical signs and symptoms.Therefore,it is
possible to use less stressful provocative procedures,
which further increases subjects’ comfort and compliance.
Symptom provocation in HVs must comply with some
basic rules (Table II),as stated by D’Souza et al.
11 In the
context of drug development,a model must also induce
target signs and symptoms in a reasonable proportion of
HVs.These signs and symptoms must be accompanied
with reliable functional changes, which can be used as
biomarkers and display low interindividual and mostly
intraindividual variability, to warrant good test–retest
reliability and permit the assessment of drugs effects in
a crossover,placebo-controlled design.
Although the principle of a POC approach in HVs is
appealing,we must be cautious in putting it into practice.
Even when the provocation procedure is simple (eg,a sin-
gle agent with well-known neurochemical properties,in
the case of a pharmacological model),the totality of the
neurochemical consequences of its administration are sel-
dom known.The same holds for the new compound stud-
ied and for its interaction with the challenge.As a conse-
quence,a positive result (ie,reversal or prevention of the
challenge’s effects by the new drug) is undoubtedly a clue
to efficacy,but a negative result can hardly be taken as the
basis for a “no-go” decision.This often makes pharma-
ceutical companies reluctant to add a POC study in HVs
to their development plan,arguing that,in case of negative
results,it could merely delay it and increase costs.In fact,
introducing POC studies in HVs implies further enhanc-
ing the global phase 1 scheme (Table I).In this “enhanced
development plan,” the single-dose study has the same
design and goals as the regular one.The repeated-dose
study merges the former repeated-dose and PD HV stud-
ies,ie,it is conducted according to a crossover (per dose),
placebo-controlled design.Provided that a single admin-
istration study has shown good tolerability in an HV group
close to the target population (eg,elderly HVs for cogni-
tive enhancers), this study can be conducted in such a
group.A model,if available,can also be used in this study,
by adding an administration the day after the classic PK
and PD assessments. This avoids wasting HVs and
resources,and maximizes the chances of positive results;
however,it requires paying close attention to tolerability
and safety, which must be verified before a challenge is
added to a repeated-administration study.
Models at FORENAP
Few models are available for routine use in drug devel-
opment.We have launched a program to adapt existing
models for this purpose(Table III),following the princi-
ples described above.Below we discuss the rationale for
each of these models,as well as preliminary results when
available,at least those which are not covered by confi-
dentiality agreements.
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Table II. Criteria to justify symptom provocation in humans.
11
• The safety and protection of subjects is ensured
• The study is expected to provide information of critical
value
• The proposed methodology is undoubtedly adequate to
answer the question (testable hypotheses, reliable and
valid measures, adequate power, appropriate data analy-
sis, and relevant controls)
• The study is the best or only feasible method of answering
the questionAlzheimer’s disease and age-related cognitive 
impairment
The scopolamine model
The scopolamine model is based on the cholinergic
hypothesis of aging and Alzheimer’s disease (AD). Its
theoretical drawback is that scopolamine is a nonselec-
tive muscarinic blocker,whereas selective muscarinic M1
blockade could be considered to better modelize the sta-
tus of the cholinergic system in AD.
12 Nevertheless, it is
a well-established model, producing cognitive defects
close to those observed in mild AD and EEG changes
consisting of an increase in δ and—to a lesser extent—
Θ bands, and a decrease in α and β power.
13 The scopo-
lamine model has been widely used in clinical experi-
mental pharmacology,
14-23 as well as in the assessment of
cognitive enhancers.
24-40 In our hands, a 0.5-mg subcuta-
neous injection of scopolamine in young HVs induced
impairment in immediate and delayed word recall,mul-
tiple choice reaction time and accuracy, and the digit
symbol substitution test. In quantified EEG, it reduced
total power and induced an increase in δ and a decrease
in Θ,α,and β absolute power;in relative power analysis,
the δ and β band activity was increased and that of the
Θ and α bands decreased (Figure 1).An interesting fea-
ture of this model is that is can be reversed or prevented
not only by cholinomimetic drugs, but also, as we have
found, by compounds without direct cholinergic
effects.
30,31,38,41
The lorazepam model
Benzodiazepines (BZDs) are known to induce sedation,
psychomotor impairment, and anterograde amnesia,
leaving retention and retrieval spared.
42Although cogni-
tive impairment is a class effect,differences between dif-
ferent BZDs have been reported,independently of their
elimination half-lives.
43-45A dissociation between the cog-
nitive and sedative effects of drugs has also been
described.
46 Lorazepam has dose-related memory- and
attention-impairing effects.
43,44,47 It has been suggested
48
that the profile of lorazepam-induced cognitive impair-
ment is close to that observed in Korsakoff’s syndrome,
whereas scopolamine rather mimics AD.Some studies
47,49
were unable to distinguish the effects of lorazepam from
those of scopolamine. Both drugs were shown to have
similar effects on verbal priming
50 and in a face–name
associative encoding task,
51 and as well as on associated
functional magnetic resonance imaging (fMRI) activa-
tion patterns.On the other hand,differential effects were
found on logical reasoning, immediate and delayed
recall,
52 and priming for human faces.
53
BZDs have well-known effects on EEG. Changes in β
amplitudes seem to reflect their interaction and intrinsic
efficacy at the GABAA-BZD (GABA,γ-aminobutyric
acid) receptor complex;their effects on β and α activity
their anxiolytic,anticonvulsant,and sedative properties;
and δ-induced changes their hypnotic action.
54
In our hands, an oral dose of 2 mg lorazepam impaired
immediate and delayed word recall,multiple choice reac-
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Table III. Models available or in development at FORENAP. AD, Alzheimer’s disease; CCK-4, cholecystokinin tetrapeptide; EEG, electroencephalog-
raphy; ERP, event-related potential; fMRI, functional magnetic resonance imaging; MEG, magnetoencephalography.
Indication Method Marker Status
AD/cognition
Scopolamine EEG/ERPs Routine
Lorazepam EEG/ERPs Routine
Low-dose ketamine EEG/MEG Validation underway
Nonpharmacological method fMRI Validation underway
Anxiety
Panic CCK-4 fMRI Validation underway
Anticipatory Behavioral fMRI Validation underway
Depression
Tryptophan depletion Sleep EEG Validation completed
Schizophrenia
Apomorphine EEG Routine
Ketamine EEG/MEG Validation underwaytion time and accuracy,and digit symbol substitution test,
but had no effect on flicker fusion frequency.In quantified
EEG,lorazepam’s effects were dose-dependent in length
and intensity,increasing δand βpower,and decreasing the
power of the Θ and α frequency bands (Figure 2).
The low-dose ketamine model
Ketamine infusion produces positive,negative,and cog-
nitive symptoms reminiscent of those observed in schiz-
ophrenia.
55-65 A hypoglutamatergic state has also been
proposed as the substratum of late-stage AD.
66 Studies
focused on ketamine-induced cognitive impairment
should separate the latter from the psychotomimetic
effects of ketamine,which is possible using lower doses.
64
Nonpharmacological approaches
Functional (positron emission tomography [PET] and
fMRI) studies on the neural correlates of cognitive aging
basically describe two cases.
67 In one,performance and
brain activation during the task are lower than in young
controls; this is also the case for episodic memory and
conflict resolution tasks.The second consists of preserved
performances associated with enlarged activation,engag-
ing more brain regions,such as during working memory
tasks.Our fMRI activation maps,obtained during a spa-
tial “n-back” working memory challenge are in agree-
ment with these data (Figure 3).Our hypothesis is that
activation patterns in elderly volunteers should be closer
to those of young volunteers after administration of a
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Figure 1. Effect of scopolamine (0.5 mg subcutaneously) on electroencephalogram (EEG) in 12 healthy young men. Placebo and scopolamine were
administered according to a crossover, double-blind design. EEG was recorded from 28 electrodes during the first 3 min in vigilance-con-
trolled conditions, and then at rest. Analog filtering 1 to 70 Hz, 12 dB/octave; digitalization with a 256-Hz sampling frequency; fast Fourier
transform on each 2-s artifact-free epochs. δ, 0.5-3.5 Hz; Θ, 4-7.5 Hz; α, 8-12.5 Hz; β, 13-32 Hz. Maps displayed are P values after scopo-
lamine–placebo comparison. Scopolamine reduced total power (not shown) and induced an increase in δ and a decrease in Θ, α, and β
absolute power; in relative power analysis, the δ and β bands’ activity was increased and that of the Θ and α bands decreased. R, at rest; VC,
in vigilance-controlled conditions.
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Absolute power Relative powercognitive enhancer.Indeed,PET scan and fMRI studies
in young volunteers have shown that physostigmine infu-
sion improved working memory performances and
reduced task-related activation.
68-70
Anxiety
Panic attack model:CCK-4
The idea of using cholecystokinin tetrapeptide (CCK-4)
as a panic probe came from experiments showing that
BZDs antagonized CCK-8S in the rat,
71 as well as from
the serendipitous finding that a 70-µg CCK-4 injection
produced panic-like feeling in healthy humans.
72 In sub-
sequent studies,
73-91 CCK-4 induced panic attacks in 0%
to 70% of HVs and these attacks were quantitatively and
qualitatively similar to those reported by patients.Attack
incidence and severity of symptoms were dose-depen-
dent, although discordant results have been described
with the same dose and a considerable overlap exists in
the rate of response to different doses.The dose of 50 µg
seems to give the most homogeneous response rate,rang-
ing from 47% to 65%.Test–retest reliability has been
poorly assessed.Two studies—although not specifically
designed for this purpose—reported a decrease in the
number and intensity of panic symptoms,
79,88 as well as in
the incidence of panic attacks.
79
In HVs,lorazepam prevented CCK-4–induced panic,
73 as
did the CCK-4 receptor antagonist CI988,
80 propranolol,
87
ondansetron after acute but not repeated administra-
tion,
88 atrial natriuretic peptide,
89 and vigabatrin.
90 PET
scan studies found an increased cerebral blood flow con-
comitant of anxiety response in the claustrum-insular-
amygdala region bilaterally and in cerebellar vermis and
anterior cingulate gyrus.
92,93 Our fMRI results confirm
these data.
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Figure 2. Effects of three oral doses of lorazepam on electroencephalogram (EEG) in 20 young healthy male volunteers. Lorazepam 0.5 mg, 1 mg, and
2 mg, and placebo were administered according to a crossover, double-blind design. Maps displayed are P values after lorazepam–placebo
comparison. In absolute power analysis, lorazepam dose-dependently decreased Θ and α power, and increased β activity. Relative power dis-
closed an additional effect on δ power which was, also dose-dependently, increased. See Figure 1 for methods and maps color code. *Time
post-administration. R, at rest; VC, in vigilance-controlled conditions.
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Relative powerAnticipatory anxiety:behavioral model
Recent research suggests that the neurophysiological
mechanisms underlying anxiety disorders are closely
related—if not identical—to those underlying the emotion
of fear.
94This provides the rationale for using behavioral
models based on fear induction or anticipation of an aver-
sive stimulus. In behavioral models, an anxious state is
induced by presentation of stimuli having an aversive
emotional content, via any sensory modality. A major
drawback of using intrinsically fearful stimuli is that the
fear or aversion elicited can vary according to volunteers’
traits and experiences.Aversive conditioning (in which an
emotionally neutral or conditioned stimulus [CS] is paired
with an aversive—or unconditioned—one [UCS],usually
in different sensory modalities) allows for a more homo-
geneous response within the subject population by adjust-
ing the aversive nature of the UCS on an individual basis.
Although amygdala activation is considered to be central
to anticipatory anxiety,
94-96 other regions are also activated
during classical conditioning,eg,right orbitofrontal,dor-
solateral prefrontal,inferior and superior frontal,inferior
and middle temporal cortices,and left superior frontal cor-
tices,
97,98 anterior cingulate,and insula,
99 according to the
paradigm used.The study of many regions together can
lessen the consequences of “missing”the amygdaloid com-
plex activation,which is transient even when the UCS con-
tinues to be presented in association with CS.
95,98,99 Our
results confirm the merits of this approach.
Depression: the tryptophan depletion challenge
The rationale and results of a recent study with this
model are given elsewhere in this volume.
100
Schizophrenia
The apomorphine model
For decades,dopamine transmission abnormalities have
been thought to be involved in the pathophysiology of
schizophrenia,
101 justifying the stimulation of dopaminer-
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Figure 3. Statistical parametric maps (SPMs) of the group analysis (4 young and 4 elderly healthy male volunteers, 3 functional magnetic resonance
imaging [fMRI] exams per subject) during “n-back” spatial working memory task versus control. In the control condition (“0-back”), subjects
had to respond when a square appeared in a given position on the computer screen; in the “1-back” condition, when it appeared in the
same place as 1 screen before; in the “2-back” condition when it appeared in the same place as 2 screens before. In both the 1-back and
the 2-back tasks, accuracy score was similar in elderly and young subjects. Reaction time was similar in the two groups during the 1-back
task, but significantly longer in the elderly group during the 2-back task. Significant activity (t-score>4) is displayed upon anatomical axial T1
images after being transformed to standardized Talairach space.
2-back
Young
Elderly
Young
Elderly
1-backgic pathways as a model of schizophrenia in HVs.
Apomorphine,a nonselective dopaminergic agonist,has
a rapid phase of absorption and distribution in the periph-
ery (20 min) as well as the brain compartment (30 min) in
humans
102 and is an ideal pharmacological tool because it
has minor psychotropic effects in both HVs and psychi-
atric patients. We have characterized apomorphine-
induced topographic changes in neurophysiological mark-
ers using a 28-lead multielectrode montage in HVs.To
ensure that observed modifications are of central and not
of peripheral origin,subjects were pretreated with dom-
peridone,a dopamine antagonist that does not cross the
blood–brain barrier.We assessed drug-induced modifica-
tions in EEG/event-related potential measurements at
different time points after subcutaneous injection of apo-
morphine.
103As expected,the effects of apomorphine on
EEG were partially opposite to those reported for clas-
sic
104 and atypical
105,106 neuroleptics,with an increase in fast
β power and decrease in Θ relative power.This model was
validated using haloperidol,which antagonized the acute
effects of apomorphine.
107
The ketamine model
N-Methyl-D-aspartate (NMDA) receptor blockade by ket-
amine infusion in HVs is acknowledged to be a good model
of schizophrenia,reproducing positive,negative,and cog-
nitive symptoms.
55-65 Despite evidence that ketamine mod-
ulates dopamine striatal concentration,
108-111 its clinical
effects were not reversed by haloperidol in patients
112 or in
HVs,
61 or olanzapine,
113 but were blunted by clozapine in
patients with schizophrenia.
114 This inconsistent effect of
antipsychotics could be dose-related.The above studies
used ketamine doses of 0.1 to 0.9 mg/kg in bolus or 1-h infu-
sion,whereas we use 0.16 to 0.54 mg/kg in a 2-h infusion.
Conclusion
There is an agreement on the need to increase the effi-
ciency of drug development.Whatever the improvements
in the chemical and preclinical steps,clinical development
strategy remains critical.Human models in HVs are obvi-
ously not a panacea.They are not applicable to any situa-
tion and the validity of the different provocation proce-
dures is uneven.Their optimal use is within what we call
an “enhanced development plan,” which requires
improvements in safety data processing. Nevertheless,
when properly used, human models can secure phase 1
study results,be of help in a “go”(more than in a “no-go”)
decision,and therefore improve the safety and efficiency
of patient studies,leading to a reduction in both time and
resources. ❏
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Modelos humanos como herramientas para
el desarrollo de fármacos psicotrópicos
A pesar de los crecientes recursos dedicados a la
investigación y desarrollo, y al refinamiento en las
etapas preclínicas, la eficiencia del desarrollo de fár-
macos para el sistema nervioso central (SNC) ha
desilusionado. Muchos fármacos llegan a estudiarse
en pacientes con una indicación terapéutica erró-
nea y/o en dosis incorrectas. Además de los prime-
ros estudios clínicos que se realizan en voluntarios
sanos y que se enfocan sólo a la seguridad, tole-
rancia y farmacocinética, el desarrollo de fármacos
depende principalmente de los estudios en pacien-
tes. Los trastornos psiquiátricos se caracterizan por
su heterogeneidad y la alta proporción de comor-
bilidad. Cada vez es más difícil reclutar pacientes
para ensayos clínicos y hay muchos factores de con-
fusión en esta población; por ejemplo, los relacio-
nados con los tratamientos. A fin de reducir al
mínimo la exposición del paciente y el gasto finan-
ciero, es importante evitar estudios mal diseñados
y no concluyentes. Este riesgo podría ser minimi-
zado al obtener datos precozmente durante el
desarrollo y al considerar que el objetivo en la fase
1 del plan es llegar a los estudios en pacientes con
las ideas claras acerca del perfil farmacodinámico
del compuesto, su eficacia en la probable indicación
(proof of concept), y relaciones entre farmacodiná-
mica y farmacocinética, además de la seguridad,
tolerancia y farmacocinética. Los modelos humanos
en voluntarios sanos pueden constituir herramien-
tas útiles para este propósito, pero su empleo nece-
sita de una adaptación global del esquema de la
fase 1, favoreciendo las evaluaciones farmacodiná-
micas sin descuidar la seguridad. Nosotros estamos
comprometidos en un programa de investigación y
desarrollo orientado a adaptar modelos existentes
y a desarrollar nuevos paradigmas que se adecuen
a una precoz verificación de la proof of concept.
Les modèles humains comme outil du 
développement des médicaments
psychotropes
Malgré l’augmentation des moyens consacrés à la
recherche et au développement (R et D) et au per-
fectionnement des phases précliniques, l’efficacité
du développement des médicaments du système
nerveux central (SNC) est décevante. De nombreux
médicaments atteignent le stade d’étude chez le
sujet malade avec une indication thérapeutique
fausse et/ou des doses incorrectes. En dehors des
premières études cliniques, qui sont conduites chez
le volontaire sain et mettent l’accent uniquement
sur la sécurité, la tolérance et la pharmacocinétique,
le développement des médicaments repose princi-
palement sur les études cliniques chez le sujet
malade. Les troubles psychiatriques se caractérisent
par une hétérogénéité et un taux élevé de comor-
bidité. Le recrutement de patients pour des essais
cliniques devient de plus en plus difficile et il existe
de nombreux facteurs confondants dans cette
population, par exemple ceux liés aux traitements.
Il est important d’éviter les études mal conçues et
peu concluantes pour limiter au maximum l’expo-
sition des patients et les dépenses financières. Ce
risque peut être minimisé en recueillant des don-
nées pharmacodynamiques plus tôt au cours du
développement et en considérant que l’objectif des
études de phase 1 est d’aboutir à des études chez
le sujet malade avec des idées claires en ce qui con-
cerne le profil pharmacodynamique du composé,
son efficacité dans l’indication probable (preuve de
concept), et les relations pharmacocinétique/phar-
macodynamie, en plus de la sécurité, de la tolé-
rance et de la pharmacocinétique. À cet effet, les
modèles humains chez le volontaire sain peuvent
être un outil utile, mais leur utilisation nécessite
une adaptation globale du schéma de phase 1,
favorisant les évaluations pharmacodynamiques
sans négliger la sécurité. Nous sommes engagés
dans un programme de R et D visant à adapter les
modèles existants et à développer de nouveaux
paradigmes capables d’établir à un stade précoce la
preuve de concept.Clinical research
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